Bio-Techne Corp (TECH) - Total Assets
Based on the latest financial reports, Bio-Techne Corp (TECH) holds total assets worth $2.59 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio-Techne Corp - Total Assets Trend (1989–2026)
This chart illustrates how Bio-Techne Corp's total assets have evolved over time, based on quarterly financial data. Also see TECH market cap overview for the company's overall valuation and market capitalisation.
Bio-Techne Corp - Asset Composition Analysis
Current Asset Composition (June 2026)
Bio-Techne Corp's total assets of $2.59 Billion consist of 27.8% current assets and 72.2% non-current assets. Review debt load of Bio-Techne Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $220.50 Million | 8.2% |
| Inventory | $195.74 Million | 7.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $303.46 Million | 11.3% |
| Goodwill | $975.36 Million | 36.4% |
Asset Composition Trend (1989–2026)
This chart illustrates how Bio-Techne Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See TECH stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Techne Corp's current assets represent 27.8% of total assets in 2026, a decrease from 86.9% in 1989.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2026, down from 16.4% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 1989.
- Asset Diversification: The largest asset category is goodwill at 36.4% of total assets.
Bio-Techne Corp Competitors by Total Assets
Key competitors of Bio-Techne Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
ChemPartner PharmaTech Co Ltd
SHE:300149
|
China | CN¥2.04 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
USA | $22.38 Million |
Bio-Techne Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.55 | 3.46 | 4.06 |
| Quick Ratio | 3.35 | 2.38 | 3.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $580.70 Million | $432.45 Million | $409.76 Million |
Bio-Techne Corp - Advanced Valuation Insights
This section examines the relationship between Bio-Techne Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.38 |
| Latest Market Cap to Assets Ratio | 4.23 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | $2.68 Billion |
| Market Capitalization | $11.33 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Bio-Techne Corp's assets at a significant premium (4.23x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Bio-Techne Corp's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bio-Techne Corp (1989–2026)
The table below shows the annual total assets of Bio-Techne Corp from 1989 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $2.68 Billion | +4.74% |
| 2025-06-30 | $2.56 Billion | -5.40% |
| 2024-06-30 | $2.70 Billion | +2.47% |
| 2023-06-30 | $2.64 Billion | +14.99% |
| 2022-06-30 | $2.29 Billion | +1.41% |
| 2021-06-30 | $2.26 Billion | +11.61% |
| 2020-06-30 | $2.03 Billion | +7.60% |
| 2019-06-30 | $1.88 Billion | +18.28% |
| 2018-06-30 | $1.59 Billion | +2.35% |
| 2017-06-30 | $1.56 Billion | +37.82% |
| 2016-06-30 | $1.13 Billion | +6.22% |
| 2015-06-30 | $1.06 Billion | +23.29% |
| 2014-06-30 | $862.49 Million | +10.85% |
| 2013-06-30 | $778.10 Million | +8.17% |
| 2012-06-30 | $719.32 Million | +16.46% |
| 2011-06-30 | $617.67 Million | +19.05% |
| 2010-06-30 | $518.82 Million | +9.92% |
| 2009-06-30 | $472.00 Million | -6.97% |
| 2008-06-30 | $507.37 Million | +11.55% |
| 2007-06-30 | $454.84 Million | +22.76% |
| 2006-06-30 | $370.51 Million | +25.49% |
| 2005-06-30 | $295.26 Million | -9.28% |
| 2004-06-30 | $325.46 Million | +23.62% |
| 2003-06-30 | $263.28 Million | +10.51% |
| 2002-06-30 | $238.25 Million | +10.54% |
| 2001-06-30 | $215.53 Million | +19.46% |
| 2000-06-30 | $180.41 Million | +45.73% |
| 1999-06-30 | $123.80 Million | +69.82% |
| 1998-06-30 | $72.90 Million | +35.25% |
| 1997-06-30 | $53.90 Million | +21.40% |
| 1996-06-30 | $44.40 Million | +30.21% |
| 1995-06-30 | $34.10 Million | +27.24% |
| 1994-06-30 | $26.80 Million | +31.37% |
| 1993-06-30 | $20.40 Million | +29.94% |
| 1992-06-30 | $15.70 Million | +63.54% |
| 1991-06-30 | $9.60 Million | +20.00% |
| 1990-06-30 | $8.00 Million | +31.15% |
| 1989-06-30 | $6.10 Million | -- |
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of l… Read more